InfuSystem Announces Financial Results for First Quarter 2026
InfuSystem swung to profitability in the first quarter with net income of $1.0 million, or $0.05 per share, compared to a net loss of $0.3 million in the prior year, despite a 3% decline in total revenue to $33.7 million. The decline in revenue was attributed to a strategic restructuring of the GE Healthcare biomedical services contract, which management stated improved overall profitability by reducing expenses more significantly than revenue.
Key figures
- Eps
- 0.05
- Revenue
- 33684000
- Guidance
- Full year 2026 pro-forma net revenue growth 6% to 8%; Adjusted EBITDA margin mid-to-low 20s
- Revenue Yoy
- -3%
- Gross margin
- 58%
- Gross profit
- 19700000
- Adjusted ebitda
- 6400000
- Adjusted ebitda margin
- 18.9%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.